Viatris agreed to buy Pacira BioSciences for $1.65 billion, adding commercial-stage non-opioid pain treatments as generics pressure continues to reshape the pain market. The deal signals continued consolidation around revenue-generating brands and pipeline follow-ons. In parallel, Roche is changing tactics in China by partnering with Defand Therapeutics on molecular glue discovery rather than simply licensing clinical candidates. The collaboration is structured around discovery and development of new oncology and immune-driven medicines, highlighting how “partner-to-build” models are gaining momentum.